Search Clinical Trials in the European Union

Duration
Visits
Safety phase (I)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
441-460 of 936 trials

Advanced Solid Tumors: ART0380 Oral Treatment

We are studying the safety and effectiveness of the oral medication ART0380 for patients with advanced or metastatic solid tumors. This includes testing it alone and in combination with other drugs to see how well it works.

Advanced or Metastatic Solid TumoursSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncology

Rheumatoid Arthritis: Abatacept and Daratumumab Treatment

We are studying a combination of two medications to see if it is safe and effective for people with rheumatoid arthritis who have specific antibodies. This research aims to explore new ways to manage autoimmunity in these patients.

Rheumatoid Arthritis6-12 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesInternal MedicineRheumatology

Myelofibrosis: Tasquinimod Treatment Study

We are studying tasquinimod in patients with myelofibrosis who are not responding to current treatments. The goal is to see if it can safely reduce spleen size and improve symptoms.

Myelofibrosis3-6 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

B-Cell Lymphoma: KITE-363 and KITE-753 Study

We are investigating the safety and dosing of two new drugs for individuals with relapsed or refractory B-cell lymphoma. This study aims to gather important information to improve treatment options.

B-cell Lymphoma RefractorySafety phase (I)Oncology

Hodgkin's Lymphoma: Atezolizumab and BEGEV Treatment

We are studying a new combination treatment for patients with relapsed or refractory Hodgkin's lymphoma to see if it helps improve response rates before stem-cell transplantation. This trial will also evaluate the safety and tolerability of this treatment approach.

Hodgkin's Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

NVDX3 Implant: Long-Term Safety Study

We are examining the long-term safety of the NVDX3 osteogenic implant made from human tissue. This study aims to ensure it is safe for patients who may need this type of treatment.

Low Grade Degenerative Lumbar SpondylolisthesisDistal Radius Fracture>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOrthopedics and Traumatology

Myeloma Treatment: SAR446523 Injection

We are investigating a new injection for adults with relapsed or refractory myeloma. The study aims to determine its safety and effectiveness compared to current treatments.

Refractory Plasma Cell Myeloma>2 yearsSafety phase (I)HematologyOncology

Advanced NSCLC: NVL-520 Treatment Study

We are testing a new medication, NVL-520, for patients with advanced ROS1-positive solid tumors, including non-small cell lung cancer. The study aims to find the best dose and evaluate its effectiveness and safety.

Advanced ROS1-positive Lung CancerSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

Multiple Myeloma: Belantamab Mafodotin and Venetoclax Combination

We are testing a new combination treatment for patients with relapsed and refractory t(11;14) multiple myeloma. The goal is to see if this approach improves outcomes compared to current therapies.

Relapsed/Refractory Multiple Myeloma>2 yearsSafety phase (I)Efficacy phase (II)HematologyOncology

Type 1 Diabetes: Study of NNC0363-1063

We are researching a new medicine to see how it affects healthy participants and those with type 1 diabetes. This study aims to gather information that could improve diabetes treatment.

Type 1 Diabetes1-2 yearsSafety phase (I)DiabetologyEndocrinology

Crohn's Disease: Stem Cell Treatment Study

We are exploring the use of fat-derived stem cells to treat fistulas in people with Crohn's disease. The goal is to find the best dose that may help improve healing.

Crohn’s Fistula1-2 yearsSafety phase (I)Efficacy phase (II)GastroenterologyInternal Medicine

Tarlatamab for Extensive Stage Small Cell Lung Cancer

We are testing a new subcutaneous treatment for individuals with extensive stage small cell lung cancer. The goal is to see how well it works compared to current options.

Extensive Stage Small Cell Lung Cancer>2 yearsSafety phase (I)Oncology

Tozorakimab: Syringe vs. Autoinjector Study

We are comparing how well Tozorakimab works when given through a prefilled syringe versus an autoinjector. This study aims to understand the differences in how the body absorbs the medication.

InflammationRespiratory Issues6-12 monthsSafety phase (I)Pulmonology

B Cell Lymphoma: CAR20(NAP)-T Therapy

We are evaluating a new CAR-T cell therapy for patients with relapsed or refractory B cell lymphoma. The study aims to assess its safety and effectiveness in treating this condition.

Non-Hodgkin's LymphomaSafety phase (I)Efficacy phase (II)Oncology

Tremelimumab Injection for Early-Stage Lung Cancer

We are studying a new injection method for delivering tremelimumab to patients with early-stage non-small cell lung cancer. The goal is to evaluate its safety and how well it works in the body.

Non-small cell lung cancer1-2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesOncologyPulmonology

Recurrent Solid Tumors: OBT076 Treatment Study

We are testing the safety and effectiveness of OBT076 in patients with recurrent or metastatic CD205-positive solid tumors. This study will also explore how it works with another treatment called balstilimab.

Malignant Solid Tumor1-2 yearsSafety phase (I)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Relapsed Primary CNS Lymphoma: High-Dose Methotrexate with Glucarpidase

We are exploring a new treatment approach for patients with relapsed primary CNS lymphoma. This study aims to assess the safety of combining high-dose methotrexate with glucarpidase.

Primary Central Nervous System Lymphoma>2 yearsSafety phase (I)Oncology

OT-A201 for Blood Cancers and Solid Tumors

We are testing a new treatment called OT-A201 in patients with certain blood cancers and solid tumors. This study aims to understand its safety and effectiveness in humans.

Relapsed or Refractory Hematological Malignancies and Advanced Solid Tumors>2 yearsSafety phase (I)Oncology

Prostate Cancer: Neoadjuvant Xaluritamig Study

We are testing a new treatment called Xaluritamig for men with newly diagnosed localized intermediate or high-risk prostate cancer. The goal is to see how well it works before surgery.

Localized Intermediate or High-Risk Prostate Cancer>2 yearsSafety phase (I)Oncology

Alpha-1 Antitrypsin Deficiency: WVE-006 Treatment

We are testing a new treatment called WVE-006 for people with Pi*ZZ Alpha-1 Antitrypsin Deficiency. The study aims to evaluate its safety and how the body responds to it.

Alpha-1 Antitrypsin Deficiency6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesEndocrinologyGastroenterologyHepatologyInternal MedicinePulmonology